Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T
Third Department of Internal Medicine, University of Tokushima, School of Medicine, Japan.
Br J Cancer. 1995 May;71(5):1095-8. doi: 10.1038/bjc.1995.212.
Serum interleukin 6 (IL-6) levels were measured in 75 patients with lung cancer and in 20 patients with benign lung diseases. IL-6 was detectable in 29 patients with lung cancer (39%), but was not detectable in any of the patients with benign lung diseases. Serum C-reactive protein levels and plasma fibrinogen levels were significantly higher and serum albumin concentration was significantly lower in lung cancer patients with detectable serum IL-6 levels than in those without detectable serum IL-6 levels and in patients with benign lung diseases. On the other hand, no significant difference was observed in blood platelet counts in these three groups. Moreover, serum IL-6 levels were not significantly different in lung cancer patients with or without clinically demonstrated distant metastasis. These results suggest that IL-6 may be a mediator of various reactions including an inflammatory response in lung cancer patients.
对75例肺癌患者和20例良性肺部疾病患者的血清白细胞介素6（IL-6）水平进行了检测。29例肺癌患者（39%）可检测到IL-6，但在任何良性肺部疾病患者中均未检测到。血清IL-6水平可检测的肺癌患者的血清C反应蛋白水平和血浆纤维蛋白原水平显著高于血清IL-6水平不可检测的肺癌患者以及良性肺部疾病患者，而血清白蛋白浓度则显著低于后两者。另一方面，这三组患者的血小板计数未观察到显著差异。此外，有或无临床证实远处转移的肺癌患者血清IL-6水平无显著差异。这些结果表明，IL-6可能是肺癌患者包括炎症反应在内的各种反应的介质。
